Jefferies Comments on Immunogen (IMGN) Following ESMO Meeting, Positive Feedback on T-DM1
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Jefferies is maintaining its Buy rating and $19 price target on shares of Immunogen Inc. (NASDAQ: IMGN) following the ESMO meeting.
The firm spoke with six breast cancer physicians about the Phase2 profile for IMGN’s T-DM1 and notes that all "strongly endorsed the safety profile as significantly better than standard therapy and the PFS benefit as robust."
One of the presenters at the ESMO called T-DM1 the "most promising" as it had the "best data so far." Five out of the six that Jefferies spoke with claim ed that its clinical profile may drive adoption in metastatic breast cancer.
An analyst at Jefferies comments, "we learned a Phase 3 trial of T-DM1 in the adjuvant setting is already in the planning stages. We also heard that the T-DM1 adjuvant study may test combination use with pertuzumab in at least one arm, which two physicians singled out as potentially the most potent regimen in development for HER2 positive breast cancer."
For more ratings news on Immunogen Inc. click here and for the rating history of Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $11.63 yesterday.
The firm spoke with six breast cancer physicians about the Phase2 profile for IMGN’s T-DM1 and notes that all "strongly endorsed the safety profile as significantly better than standard therapy and the PFS benefit as robust."
One of the presenters at the ESMO called T-DM1 the "most promising" as it had the "best data so far." Five out of the six that Jefferies spoke with claim ed that its clinical profile may drive adoption in metastatic breast cancer.
An analyst at Jefferies comments, "we learned a Phase 3 trial of T-DM1 in the adjuvant setting is already in the planning stages. We also heard that the T-DM1 adjuvant study may test combination use with pertuzumab in at least one arm, which two physicians singled out as potentially the most potent regimen in development for HER2 positive breast cancer."
For more ratings news on Immunogen Inc. click here and for the rating history of Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $11.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
